Resumen de Optimization of thrombolytic therapy in brain pathology
Ischemic stroke is the leading cause of disability in the developed countries. The only approved drug treatment is the recombinant tissue plasminogen activator (rtPA). However, its use is limited due to the short half-life side effects. In this study we have developed rtPA-loaded nanocapsules combined with ultrasound application, which we used as trigger to induce rtPA from our nanocapsules. These nanocapsules were also able to extend the half-life of rtPA after in vivo administration and reach the ischemic region. Overall, we have developed promising nanocapsules for the triggered release of rtPA in the brain with potential application in ischemic stroke.
